ArticleInternational journal of clinical oncology2026
Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab plus lenvatinib is a standard first-line treatment option for advanced renal cell carcinoma (RCC), but data focused on patients aged ≥ 75 years remain limited. We evaluated the efficacy, safety, and treatment feasibility of this regimen in a Japanese multicenter cohort.
methodsWe retrospectively analyzed 170 patients with metastatic or unresectable RCC treated with first-line pembrolizumab plus lenvatinib. We compared those aged ≥ 75 years (n = 31) with those aged < 75 years (n = 139), assessing treatment exposure, treatment modifications, adverse events (AEs), best overall response, progression-free survival and overall survival.
resultsThe older patients more commonly received a reduced starting dose of lenvatinib (P = 0.02) and schedule modification (19% vs. 6%, P = 0.03). However, the number of lenvatinib dose reductions, final lenvatinib dose, and treatment duration were similar between the groups. There was no significant difference in any-grade AEs, grade ≥ 3 AEs, corticosteroid use for immune-related AEs, or AE-related treatment discontinuation. The objective response rate was 77% in patients aged ≥ 75 years and 65% in those aged < 75 years (P = 0.20). Progression-free survival and overall survival were also comparable (P = 0.92 and P = 0.58, respectively), and age ≥ 75 years was not associated with progression-free survival or overall survival in multivariable analysis.
conclusionsOur results suggest that pembrolizumab plus lenvatinib can be feasibly administered to selected patients aged ≥ 75 years through individualized dose attenuation and schedule modification without an apparent loss of efficacy or increase in severe toxicity.
Indexed as
Identifiers
42377813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.